{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:28:57Z","timestamp":1787905737799,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009827","name":"Alexandria University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The global rise of antimicrobial resistance (AMR) threatens infection treatment. Methicillin-resistant <jats:italic>Staphylococcus<\/jats:italic> species (MRSS) are particularly challenging. This study examines the relative consumption of Linezolid (Reserve antibiotic) versus Vancomycin and Teicoplanin (Watch antibiotics) for MRSS, comparing trends with resistance patterns to optimize antibiotic use and combat AMR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This observational retrospective study analyzed trends in the consumption of Vancomycin, Linezolid, and Teicoplanin among all patients admitted to a tertiary hospital in Alexandria, Egypt from January 2019 to December 2023. The study compared these consumption patterns with resistance rates in <jats:italic>Staphylococcus<\/jats:italic> spp., including MRSS, from January 2020 to December 2023. Data on antibiotic consumption, expressed as defined daily doses per 1000 patient days (DDD\/1000PD), were retrieved from pharmacy records, while resistance data were obtained from the WHONET database. Exploratory data analysis, including time series visualization and linear regression, assessed trends and the impact of COVID-19 on antibiotic use and resistance patterns.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Linezolid consumption increased significantly (\u03b2\u2009=\u20093.72, 95% CI: 0.50 to 6.94, <jats:italic>p<\/jats:italic>\u2009=\u20090.027), while Teicoplanin consumption also rose but to a lesser extent (\u03b2\u2009=\u20091.81, 95% CI: 1.02 to 2.60, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Vancomycin consumption remained stable (\u03b2 = -0.31, 95% CI: -0.77 to 0.15, <jats:italic>p<\/jats:italic>\u2009=\u20090.184). Overall, Linezolid experienced an increase in usage that was 2.5 times steeper compared to the combined use of Vancomycin and Teicoplanin. The ICU surveillance data indicated that the days of Vancomycin therapy per 1000 patient days decreased significantly (\u03b2 = -5.02, 95% CI: -6.79 to -3.25, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Methicillin resistance remained high ranging from 47.8 to 85.2%. Throughout the study period, resistance to the three antibiotics was higher than resistance rates reported in other published studies across Egypt while remained stable and comparable between the hospital and ICU. In the hospital, resistance ranged from 4 to 23.7% for Vancomycin, 6.3\u201328.6% for Linezolid, and 0\u201341.7% for Teicoplanin. In the ICU, Vancomycin resistance ranged from 5.5 to 34.2%, Linezolid from 11.4 to 41.2%, and Teicoplanin from 7.1 to 38.8%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study underscores the urgent need for antimicrobial stewardship to reduce Linezolid overuse and address persistently high resistance rates against all anti-MRSA antibiotics.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13690-025-01614-3","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T08:36:43Z","timestamp":1747211803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating anti-MRSA antibiotic stewardship with a focus on trends in consumption and resistance in a tertiary hospital in Alexandria, Egypt from 2019 to 2023"],"prefix":"10.1186","volume":"83","author":[{"given":"Ehab","family":"Elmongui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amel","family":"Elsheredy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa Abd","family":"Elhameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"1614_CR1","unstructured":"WHO. Global antimicrobial resistance and use surveillance system (GLASS) report [Internet]. 2022. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240062702"},{"key":"1614_CR2","unstructured":"CDC. Antimicrobial Resistance Threats in the United States, 2021\u20132022 [Internet]. 2024. Available from: https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/update-2022.html"},{"key":"1614_CR3","doi-asserted-by":"publisher","unstructured":"David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23(3):616\u201387. Available from: https:\/\/doi.org\/10.1128\/cmr.00081-09","DOI":"10.1128\/cmr.00081-09"},{"key":"1614_CR4","unstructured":"WHO. AWaRe classification of antibiotics for evaluation and monitoring of use, 2023 [Internet]. 2023. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.04"},{"key":"1614_CR5","unstructured":"WHO. The WHO AWaRe (Access, Watch, Reserve) antibiotic book [Internet]. Geneva. 2022. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240062382"},{"key":"1614_CR6","doi-asserted-by":"publisher","unstructured":"Kramer TS, Schwab F, Behnke M, Hansen S, Gastmeier P, Aghdassi SJS. Linezolid use in German acute care hospitals: results from two consecutive national point prevalence surveys. Antimicrob Resist Infect Control [Internet]. 2019;8(1):159. Available from: https:\/\/doi.org\/10.1186\/s13756-019-0617-0","DOI":"10.1186\/s13756-019-0617-0"},{"key":"1614_CR7","doi-asserted-by":"publisher","unstructured":"Dentan C, Forestier E, Roustit M, Boisset S, Chanoine S, Epaulard O, et al. Assessment of linezolid prescriptions in three French hospitals. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2017;36(7):1133\u201341. Available from: https:\/\/doi.org\/10.1007\/s10096-017-2900-4","DOI":"10.1007\/s10096-017-2900-4"},{"key":"1614_CR8","doi-asserted-by":"publisher","unstructured":"Matrat L, Plaisant F, Barreto C, Claris O, Butin M. Increasing use of linezolid in a tertiary NICU during a 10-year period: reasons and concerns for the future. Antimicrob Resist Infect Control. 2020;9(1):156. Available from: https:\/\/doi.org\/10.1186\/s13756-020-00818-2","DOI":"10.1186\/s13756-020-00818-2"},{"key":"1614_CR9","doi-asserted-by":"publisher","unstructured":"Safa L, Afif N, Zied H, Mehdi D, Ali YM. Proper use of antibiotics: situation of linezolid at the intensive care unit of the Tunisian Military Hospital. Pan Afr Med J. 2016;25:196. Available from: https:\/\/doi.org\/10.11604\/pamj.2016.25.196.9476","DOI":"10.11604\/pamj.2016.25.196.9476"},{"key":"1614_CR10","doi-asserted-by":"publisher","unstructured":"Cavalcanti AB, Goncalves AR, Almeida CS, Bugano DD, Silva E. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane database Syst Rev. 2010;(6):CD007022. Available from: https:\/\/doi.org\/10.1002\/14651858.cd007022.pub2","DOI":"10.1002\/14651858.cd007022.pub2"},{"key":"1614_CR11","doi-asserted-by":"publisher","unstructured":"Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother. 2009;53(10):4069\u201379. Available from: https:\/\/doi.org\/10.1128\/aac.00341-09","DOI":"10.1128\/aac.00341-09"},{"key":"1614_CR12","doi-asserted-by":"publisher","unstructured":"Hussein RR, Rabie ASI, Bin Shaman M, Shaaban AH, Fahmy AM, Sofy MR, et al. Antibiotic consumption in hospitals during COVID-19 pandemic: a comparative study. J Infect Dev Ctries. 2022;16(11):1679\u201386. Available from: https:\/\/doi.org\/10.3855\/jidc.17148","DOI":"10.3855\/jidc.17148"},{"key":"1614_CR13","doi-asserted-by":"publisher","unstructured":"Filimonovic J, Risti\u0107 ZS, Gazibara T, Saponjic V, Dotlic J, Jovanovic V, et al. Trends and patterns of antibiotics use in Serbia from 2006 to 2021: Pre-COVID-19 period versus COVID-19 pandemic. Am J Infect Control. 2024;52(3):293\u2013304. Available from: https:\/\/doi.org\/10.1016\/j.ajic.2023.09.005","DOI":"10.1016\/j.ajic.2023.09.005"},{"key":"1614_CR14","doi-asserted-by":"publisher","unstructured":"Mustafa T, Niazi MRK, Lakdawala Z, Mirza S. Regional and National Trends in Consumption of Antimicrobials in Pakistan; Pre and Post-COVID (2019\u20132021). Clin Infect Dis an Off Publ Infect Dis Soc Am. 2023;77(Suppl 7):S569\u201377. Available from: https:\/\/doi.org\/10.1093\/cid\/ciad647","DOI":"10.1093\/cid\/ciad647"},{"key":"1614_CR15","doi-asserted-by":"publisher","unstructured":"Talaat M, El-Shokry M, El-Kholy J, Ismail G, Kotb S, Hafez S, et al. National surveillance of health care-associated infections in Egypt: Developing a sustainable program in a resource-limited country. Am J Infect Control. 2016;44(11):1296\u2013301. Available from: https:\/\/doi.org\/10.1016\/j.ajic.2016.04.212","DOI":"10.1016\/j.ajic.2016.04.212"},{"key":"1614_CR16","doi-asserted-by":"publisher","unstructured":"Abdelaziz Abdelmoneim S, Mohamed Ghazy R, Anwar Sultan E, Hassaan MA, Anwar Mahgoub M. Antimicrobial resistance burden pre and post-COVID-19 pandemic with mapping the multidrug resistance in Egypt: a comparative cross-sectional study. Sci Rep [Internet]. 2024;14(1):7176. Available from: https:\/\/doi.org\/10.1038\/s41598-024-56254-4","DOI":"10.1038\/s41598-024-56254-4"},{"key":"1614_CR17","doi-asserted-by":"publisher","unstructured":"Azzam A, Khaled H, Mosa M, Refaey N, AlSaifi M, Elsisi S, et al. Epidemiology of clinically isolated methicillin-resistant Staphylococcus aureus (MRSA) and its susceptibility to linezolid and vancomycin in Egypt: a systematic review with meta-analysis. BMC Infect Dis. 2023;23(1):263. Available from: https:\/\/doi.org\/10.1186\/s12879-023-08202-2","DOI":"10.1186\/s12879-023-08202-2"},{"key":"1614_CR18","unstructured":"WHO. Collaborating Centre for Surveillance of Antimicrobial Resistance. WHONET: The microbiology laboratory database software [Internet]. 2023. Available from: https:\/\/whonet.org\/"},{"key":"1614_CR19","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 33rd Edition [Internet]. 2023. Available from: https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m100\/"},{"key":"1614_CR20","doi-asserted-by":"publisher","unstructured":"Zhang D, Xu Y, Wang X, Hou L, Xing M, Xu S, et al. Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2023;79(10):1303\u201314. Available from: https:\/\/doi.org\/10.1007\/s00228-023-03542-z","DOI":"10.1007\/s00228-023-03542-z"}],"container-title":["Archives of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-025-01614-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13690-025-01614-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-025-01614-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T08:36:47Z","timestamp":1747211807000},"score":1,"resource":{"primary":{"URL":"https:\/\/archpublichealth.biomedcentral.com\/articles\/10.1186\/s13690-025-01614-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1614"],"URL":"https:\/\/doi.org\/10.1186\/s13690-025-01614-3","relation":{},"ISSN":["2049-3258"],"issn-type":[{"value":"2049-3258","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was granted by the ethical review board of the Medical Research Institute [IORG#: IORG0008812, Protocol serial number: E\/C. S\/N. T84\/2023]. A waiver of informed consent was provided since all data were anonymized and sourced from hospital records.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}